Safety Study to Assess AFM11 in Patients With Relapsed or Refractory Adult B-precursor ALL
NCT02848911
·
clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
17
Enrollment
INDUSTRY
Sponsor class
Stopped
Strategic decision was made to terminate the AFM11 development
Conditions
Leukemia, B-Cell
Interventions
DRUG:
AFM11
Sponsor
Affimed GmbH